• We are available for your help 24/7
  • Email: info@isindexing.com, submission@isindexing.com

Paper Details


Kattula Rao Vinay Rajan*, Pilla Sree Surya Durga Devi, Penugonda Vineela, Ravisankar Pasam, Haritha Allu, Prasad Reddy M

Journal Title:World Journal of Pharmaceutical Research

Vortioxetine is a novel atypical antidepressant indicated in the treatment of Major Depressive Disorder (MDD). Vortioxetine got approval by Food and Drug Administration (FDA) for its use in MDD in the USA in September 2013. It mainly acts by serotonin reuptake inhibition. Preclinical studies demonstrated that not only does vortioxetine have an antidepressant action but also that unlike many established antidepressants it may have cognition-enhancing effects and vortioxetine also elevates levels of the excitatory and inhibitory neurotransmitters such as serotonin, noradrenaline, dopamine, acetylcholine and histamine in specific areas of the rat brain. The most commonly noticed adverse events associated with vortioxetine treatment were nausea, headache, and dizziness. Sexual dysfunction and somnolence were also noticed in some patients. The recommended initial dose is 10mg once daily. . It should be used during pregnancy only if the potential benefit outweighs the potential risk to the foetus. This present review summarizes the pharmacology of vortioxetine.